Martin Welschof, BioInvent CEO

Ex­elix­is taps in­to can­cer an­ti­body dis­cov­er­er out of Swe­den

Ex­elix­is is dol­ing out $25 mil­lion to snag rights to choose three tar­gets found by BioIn­vent.

The Cal­i­for­nia can­cer drug­mak­er is link­ing arms with the Swedish biotech — both found­ed in the mid 90s — to ex­pand its suite of an­ti­bod­ies for im­muno-on­col­o­gy. BioIn­vent will of­fer up its can­cer im­munol­o­gy and an­ti­body bi­ol­o­gy chops and Ex­elix­is will bring its an­ti­body-drug con­ju­gate tech to the ta­ble.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.